Pericyte senescence is sufficient to weaken the BBB even without classic amyloid or tau proteinopathy
🧪 Overview
Selective induction of a senescence program in adult pericytes is sufficient to impair barrier-supportive trophic signaling, weaken endothelial tight-junction maintenance, and cause durable BBB leak that later contributes to neuronal dysfunction. This is a key causality hypothesis for deciding whether pericyte senescence is a primary lesion or mainly a reactive state.
🧬 Mechanism
Curated pathway from expert analysis
flowchart TD
A["Abeta/Tau Stress<br/>DNA Damage Signaling"]
B["CDKN2A/p16 Upregulation<br/>INK4a Locus Activation"]
C["CDK4/6 Inhibition<br/>Cyclin D Complex Blocked"]
D["RB Hypophosphorylation<br/>Cell Cycle Arrest"]
E["Cellular Senescence<br/>Permanent Growth Arrest"]
F["SASP Secretion<br/>IL6/IL8/TNF/MMP Release"]
G["Neuroinflammation<br/>Bystander Neuron Damage"]
H["ARF/p19 Expression<br/>p53 Stabilization"]
A --> B
B --> C
C --> D
D --> E
E --> F
F --> G
B --> H
H -.->|"amplifies"| E
style A fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
style G fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a⚖️ Evidence
No linked papers recorded for this hypothesis yet.
🏥 Translation
🧬 3D Protein Structure — CDKN2A
No curated PDB or AlphaFold mapping for CDKN2A yet. Search RCSB →
🧠 GTEx v10 Brain ExpressionJSON
Median TPM across 13 brain regions for CDKN2A, CDKN1A, IL6, CXCL8, TGFB1 from GTEx v10.
💉 Clinical Trials
No clinical trials data linked to this hypothesis yet.
No curated ClinVar variants loaded for this hypothesis.
Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.
No DepMap CRISPR Chronos data found for CDKN2A, CDKN1A, IL6, CXCL8, TGFB1.
Run python3 scripts/backfill_hypothesis_depmap.py to populate.
🏆 Tournament
🏆 Arenas / Elo
📊 Market Indicators
💾 Resource Usage
🔮 Predictions
| Prediction | Predicted | Observed | Status | Conf |
|---|---|---|---|---|
| IF we selectively induce pericyte senescence in adult mice using pericyte-specific PDGFRβ-CreERT2 to drive CDKN2A overexpression (tamoxifen on P60-P75), THEN we will observe statistically significant | ≥50% increase in brain parenchymal tracer accumulation in pericyte-senescent mice compared to controls | — no observation — | pending | 0.65 |
| IF we pharmacologically prevent pericyte senescence in 5xFAD amyloid model mice by administering senolytic ABT-263 (navitoclax, 50mg/kg/day via drinking water) starting at 6 months, THEN we will obser | ≥40% reduction in IL6 and CXCL8 brain concentrations; ≥30% preservation of pericyte coverage; reversal of 5xFAD cognitive deficits to WT levels | — no observation — | pending | 0.55 |
▸Metadatasource: v1_phase_c_backfill · origin_type: debate_synthesizer
| source | v1_phase_c_backfill |
| origin_type | debate_synthesizer |
| _schema_version | 1 |